A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' Buprenorphine transdermal system [BTDS]) And Placebo In Patients With Diabetic Peripheral Neuropathic Pain

Trial Profile

A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' Buprenorphine transdermal system [BTDS]) And Placebo In Patients With Diabetic Peripheral Neuropathic Pain

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms ASSET-DPNP
  • Sponsors Mundipharma International
  • Most Recent Events

    • 16 Jun 2016 Primary endpoint has not been met. (Proportion of patients from the ITT population that achieved at least a 30% reduction in NRS average pain intensity at week 12), as per results published in the Diabetes Care.
    • 16 Jun 2016 Results published in the Diabetes Care
    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top